Health Canada

Learn about the outcomes of the public consultations on the COVID-19 clinical trials Interim Order and clinical trials records retention.

IO No. 2 supports Canada’s continued focus on dealing with the significant risk that COVID-19 continues to pose to the health and safety of Canadians.

Health Canada and the Public Health Agency of Canada have been working with provinces, territories and other partners, including researchers, advocates and people with lived and living experience. The goal of this work is to help make sure that people who use(d) substances can continue to access...

Canada and the Northwest Territories agree that immediate action and collaboration was and continues to be needed among governments to expand virtual care services to support improved access to publicly insured health care services for Canadians and to work together to further accelerate the use...

Guidance document provides applicants seeking authorization to conduct COVID-19 drug clinical trials specifically around the applications guidelines and process.

IO No. 2 continues to support the optional pathway introduced by IO No. 1 to facilitate clinical trials for potential COVID-19 drugs and medical devices.

Learn more about drugs and vaccines being developed or authorized for COVID-19.

The purpose of this notice is to communicate the types of testing technologies that Health Canada considers are a priority for review.

During the pandemic, there may be more deviations from the established protocol. Despite this, it’s important to continue to protect patient safety and ensure data integrity. This notice addresses the concerns of clinical trial sponsors and Canadians.

The guidance documents contain information for applicants seeking authorization to conduct COVID-19 drug and medical device clinical trials under Interim Order (IO) No. 2.

The COVID-19 pandemic has created an urgent need for drugs, biocides, medical devices and foods for a special dietary purpose, and affected their supply in Canada. To help prevent or alleviate shortages of these products, the Minister of Health has signed an interim order (IO).

This interim order (IO) provides more tools for urgently addressing drug shortages related to COVID-19.

Interim Order No. 2 Respecting Drugs, Medical Devices, and Foods for a Special Dietary Purpose in Relation to COVID-19 (Interim Order No. 2) was signed on March 1, 2021.

Interim Order No. 2 Respecting Drugs, Medical Devices, and Foods for a Special Dietary Purpose in Relation to COVID-19 (Interim Order No. 2) was signed on March 1, 2021.

Information on the updated list of medical devices for mandatory reporting of shortages in relation to COVID-19

This guidance document supports Interim Order No. 2 Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19 (Interim Order No. 2).

Health Canada works with the Canada Border Services Agency (CBSA) to assess the compliance of health products at the border. To ensure that CBSA and Health Canada can determine if health products meet requirements, shipments should include the necessary information.

Health Canada has developed this guidance document in order to support the Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 pursuant to subsection 30.1(1) of the Food and Drugs Act. This Interim Order will allow the Department to issue expedited...

List of priority drugs currently having quantities placed in reserve to manage drug shortages for the treatment of COVID-19.

How to import and sell designated biocides, propose an addition to the list of biocides and regulatory requirements for selling designated biocides.